Phagos

Phagos uses AI and phages to create personalized bacterial treatments in 2 months. Our sustainable antibiotic alternative targets specific bacteria without resistance, serving chicken, cattle, swine, and shrimp farms worldwide.

Operating in vc portfolio based in Paris, Phagos was founded in 2021.

Profile

Phagos develops a solution against the silent pandemic of antibiotic resistance. The company developed an ML-driven bio platform unlocking unprecedented bacteriophage efficiency. Phagos combines ML predictive ability and optimised microbiology workflows to produce scalable, personalised phage therapies as an alternative to antibiotics. Their first market focus is the biggest consumer of antibiotics in the world:...

Within the vc portfolio space, the company focuses on its core offering rather than a broad product line.

The company is recorded as being based in Paris.

The company is listed at the VC-backed startup stage of development.

Website: phagos.org